Cytokine expression and the role of Th17 cells in a mouse model of colitis

He,Ying; Lin,Lian-Jie; Zheng,Chang-Qing; Jin,Yu; Lin,Yan

doi:10.3892/mmr.2012.1111

Cytokine expression and the role of Th17 cells in a mouse model of colitis

Authors:
- Ying He
- Lian-Jie Lin
- Chang-Qing Zheng
- Yu Jin
- Yan Lin
View Affiliations

Affiliations: Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: September 28, 2012 https://doi.org/10.3892/mmr.2012.1111
Pages: 1438-1442

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to explore the expression of cytokines by Th17 cells and their mechanisms of action in a mouse model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)‑induced inflammatory bowel disease (IBD). ELISA was used to detect the expression of the Th17 cytokine interleukin, (IL)-17, and that of the Th1 cytokine, interferon-γ (IFN-γ), in colon tissues. Western blot analysis was used to detect IL-17 expression in the peripheral blood mononuclear cells (PBMCs), spleen mononuclear cells (SMCs), mesenteric lymph node cells and colon tissues of the colitic mice. RT-PCR analysis was used to detect the effect of anti-IL-17 antibody application on the tumor necrosis factor (TNF)-α, IFN-γ and IL-6 mRNA levels in the SMCs of the colitic mice. The Th17 cytokine, IL-17, and the Th1 cytokine, IFN-γ, were expressed at high levels in the TNBS‑induced colitic mice. In addition, the expression of the Th17 cytokine appeared earlier than that of the Th1 cytokine. The IL-17 levels in the SMCs, mesenteric lymph node cells and colon tissues of the disease model group were significantly different from those of the normal control group (p<0.01), while the IL-17 levels in the PBMCs of the disease model group were not significantly different (p>0.05) from those of the control group. Following the application of 10 µg/ml anti‑IL‑7 antibody, the TNF-α, IL-6 and IFN-γ mRNA levels in the SMCs of the model group demonstrated no significant differences from those of the non-antibody‑treated control group (p>0.05). In conclusion, Th17 and Th1 cells are involved in TNBS-induced IBD and the effect of the Th17 cells may be mediated through the induction of the secretion of pro-inflammatory cytokines.

View Figures

View References

1	Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H and Fiocchi C: The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 21:408–413. 2005.PubMed/NCBI
2	Jiang Y, Xia B, Jiang L, et al: Association of CTLA-4 gene microsatellite polymorphism with ulcerative colitis in Chinese patients. Inflamm Bowel Dis. 12:369–373. 2006. View Article : Google Scholar : PubMed/NCBI
3	Vermeire S: Genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther. 24(Suppl 3): 2–10. 2006. View Article : Google Scholar : PubMed/NCBI
4	Weaver CT, Harrington LE, Mangan PR, Gavrieli M and Murphy KM: Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 24:677–688. 2006. View Article : Google Scholar : PubMed/NCBI
5	Harrington LE, Mangan PR and Weaver CT: Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol. 18:349–356. 2006. View Article : Google Scholar : PubMed/NCBI
6	Podolsky DK: Inflammatory bowel disease. N Eng J Med. 347:417–429. 2002. View Article : Google Scholar
7	Iwakura Y and Ishigame H: The IL-23/IL-17 axis in inflammation. J Clin Invest. 116:1218–1222. 2006. View Article : Google Scholar : PubMed/NCBI
8	Park H, Li Z, Yang XO, et al: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
9	Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM and Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24:179–189. 2006. View Article : Google Scholar
10	Langrish CL, Chen Y, Blumenschein WM, et al: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 201:233–240. 2005. View Article : Google Scholar : PubMed/NCBI
11	Yamada H: Th17 cells and human arthritic diseases. Nihon Rinsho Meneki Gakkai Kaishi. 33:214–221. 2010.(In Japanese).
12	Hue S, Ahern P, Buonocore S, et al: Interleukin-23 drives innate and T cell- tmediated intestinal inflammation. J Exp Med. 203:2473–2483. 2006. View Article : Google Scholar : PubMed/NCBI
13	Blaschitz C and Raffatellu M: Th17 cytokines and the gut mucosal barrier. J Clin Immunol. 30:196–203. 2010. View Article : Google Scholar : PubMed/NCBI
14	Zhang Z, Zheng M, Bindas J, Schwarzenberger P and Kolls JK: Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis. 12:382–388. 2006. View Article : Google Scholar : PubMed/NCBI
15	Becker C, Dornhoff H, Neufertet C, et al: Cutting edge: IL-23 Eross-rugulates IL-12 production in T cell-dependent experimental colitis. J Immunol. 177:2760–2764. 2006. View Article : Google Scholar : PubMed/NCBI
16	Davidson NJ, Leach MW, Fort MM, et al: T helper cell 1-type CD4⁺ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med. 184:241–225. 1996.PubMed/NCBI
17	Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P and Lebecque S: Interleukin-17. Int Rev Immunol. 16:541–551. 1998. View Article : Google Scholar
18	Batten M, Li J, Yi S, et al: Interleukin-27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 7:929–936. 2006. View Article : Google Scholar : PubMed/NCBI
19	Elson CO, Cong Y, Weaver CT, et al: Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 132:2359–2370. 2007. View Article : Google Scholar : PubMed/NCBI
20	Targan SR and Karp LC: Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev. 206:296–305. 2005. View Article : Google Scholar : PubMed/NCBI
21	Reddy KP, Markowitz JE, Ruchelli ED, Baldassano RN and Brown KA: Lamina propria and circulating interleukin-8 in newly and previously diagnosed pediatric inflammatory bowel disease patients. Dig Dis Sci. 52:365–372. 2007. View Article : Google Scholar : PubMed/NCBI
22	Hong DS, Angelo LS and Kurzrock R: Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 110:1911–1928. 2007. View Article : Google Scholar : PubMed/NCBI
23	Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al: Withdrawal of immunosuppression in Crohns disease treated with seheduled infliximab maintaince: a randomized trial. Gastroenterology. 134:1861–1868. 2008.PubMed/NCBI
24	Orlando A, Mocciaro F, Civitavecchia G, Scimeca D and Cottone M: Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Dig Liver Dis. 40(Suppl 2): S236–S246. 2008. View Article : Google Scholar : PubMed/NCBI